Abstract

The anti-emetic drug domperidone (Motilium - Janssen) was introduced in 1982.¹ Like metoclopramide the drug blocks dopamine receptors in the medullary chemoreceptor trigger zone, thereby influencing the central control of nausea and vomiting, and in the gut to increase gastrointestinal motility.² Parenteral domperidone which was used to prevent vomiting caused by cytotoxic drugs or postoperatively was withdrawn in 1984 because ventricular arrhythmias had followed high intravenous doses.^3,4 Oral and rectal domperidone continue to be promoted, especially since the arrival of a second brand (Evoxin - Sterling). The tablets and suppositories are licensed ‘for the treatment of acute nausea and vomiting of any aetiology, in adults’ - a remarkably broad indication. The suppositories are also for children receiving cytotoxic drugs or radiotherapy.